Risk of recurrence and bleeding in patients with cancer-associated venous thromboembolism treated with rivaroxaban: A nationwide cohort study.

Mette SøgaardPeter Brønnum NielsenFlemming SkjøthJette Nordstrøm KjaeldgaardTorben Bjerregaard Larsen

Published in: Cancer medicine (2019)

In this clinical practice setting, rivaroxaban was rarely used for cancer-associated VTE. However, among those who received rivaroxaban, the treatment appeared safe and effective with rates comparable to previous studies of selected populations.

Keyphrases

venous thromboembolism
direct oral anticoagulants
clinical practice
atrial fibrillation
pulmonary embolism
combination therapy
free survival